-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Mitoxantrone
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/65271-80-9.gif)
| Category | Orthopoxvirus |
| CAS | 65271-80-9 |
| Description | Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. It is used in the treatment of certain types of cancer, mostly metastatic breast cancer, acute myeloid leukemia, and non-Hodgkin's lymphoma. |
Product Information
| Synonyms | mitoxantrone; 65271-80-9; Mitoxanthrone; Mitozantrone; DHAQ |
| IUPAC Name | 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione |
| Molecular Weight | 444.48 |
| Molecular Formula | C22H28N4O6 |
| Canonical SMILES | C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO |
| InChI | InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2 |
| InChIKey | KKZJGLLVHKMTCM-UHFFFAOYSA-N |
| Boiling Point | 805.7±65.0 °C at 760 mmHg |
| Melting Point | 170-174°C |
| Flash Point | 441.1±34.3 °C |
| Purity | >98% |
| Density | 1.5±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Brown to black (Solid) |
| Application | Analgesics |
| Storage | 4°C, protect from light * In solvent : -80°C, 6 months -20°C, 1 month (protect from light) |
| Complexity | 571 |
| Exact Mass | 444.20088463 |
| Index Of Refraction | 1.709 |
| In Vitro | Mitoxantrone inhibits PKC in a competitive manner with respect to histone H1, and its Ki value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP. Mitoxantrone (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone is due to induction of Apoptosis. Mitoxantrone shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC50 values of 18 and 196 nM, respectively. |
| In Vivo | Mitoxantrone (IP, 0-3.2 mg/kg/day) produces a statistically significant number of 60-day survivors at 1.6 mg/kg in mice with IP implanted L1210 leukemia. Mitoxantrone (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma. |
| PSA | 163.18000 |
| Target | Topoisomerase; PKC; Orthopoxvirus; Apoptosis; Endogenous Metabolite |
| Vapor Pressure | 0.0±3.0 mmHg at 25°C |
| XLogP3-AA | 1 |
